Free tool

GLP-1 Drug Pipeline Tracker

Search 79 weight loss drugs in the GLP-1 pipeline, from first human trials to pharmacy shelves, by class, company, route and sourced status.

Jump to closest to approval, available today or FAQs

Search the pipeline

Data as of November 18, 2026

  • 13 Approved
  • 10 Submitted
  • 19 Phase 3
  • 18 Phase 2
  • 7 Phase 1
  • 12 Discontinued

79 drugs shown

GLP-1 and related weight loss drugs by class, company, status and route. Data as of November 18, 2026.
ClassDrugCompanyStatusRouteLatest status note
GLP-1 RA 21 drugs
GLP-1 RAAlbiglutide TanzeumGSKDiscontinuedInjection, weeklyTanzeum is listed as discontinued in the FDA's Drugs@FDA database; its last label supplement dates from December 2017. Source for Albiglutide
GLP-1 RABeinaglutideShanghai BenemaeApprovedInjectionChina's NMPA approved beinaglutide for adult weight management in July 2023. Source for Beinaglutide
GLP-1 RABerobenatide PF-08653944; MET-097iPfizerPhase 3Injection, weekly or monthlyPfizer's November 2026 pipeline lists it in Phase 3; the first Phase 3 trial (VESPER-4) began in December 2025. Source for Berobenatide
GLP-1 RABofanglutide GZR18Gan & Lee PharmaceuticalsInjection, every two weeksChina's NMPA accepted a marketing application for long-term weight management in September 2026. Source for Bofanglutide
GLP-1 RADulaglutide TrulicityEli LillyApprovedInjection, weeklyApproved by the FDA in September 2014 for type 2 diabetes as Trulicity; it is not approved for weight loss. Source for Dulaglutide
GLP-1 RAEcnoglutide XW003Sciwind BiosciencesApprovedInjection, weeklyChina's NMPA approved the weekly injection for chronic weight management in March 2026. Source for Ecnoglutide
GLP-1 RAEfpeglenatideHanmi PharmaceuticalApprovedInjection, weeklySouth Korea's MFDS approved it for chronic weight management in adults without diabetes in October 2026. Source for Efpeglenatide
GLP-1 RAEfsubaglutide alfa supaglutideInnogenApprovedInjection, weeklyApproved in China for type 2 diabetes in January 2025; an obesity Phase 3 finished its main follow-up in July 2026. Source for Efsubaglutide alfa
GLP-1 RAExenatide Byetta; BydureonAstraZenecaDiscontinuedInjection, twice daily or weeklyByetta and Bydureon are listed as discontinued in the FDA's Drugs@FDA database; their last supplements date from 2025. Source for Exenatide
GLP-1 RAHDM1702 semaglutide injection (Huadong)Huadong MedicineInjection, weeklyChina's NMPA accepted Huadong's application for its semaglutide injection in weight management in April 2026. Source for HDM1702
GLP-1 RALiraglutide Victoza; SaxendaNovo NordiskApprovedInjection, dailyApproved by the FDA for weight management as Saxenda in December 2014, after a 2010 diabetes approval as Victoza. Source for Liraglutide
GLP-1 RALixisenatide Adlyxin; LyxumiaSanofiDiscontinuedInjection, dailyThe EU authorization for Lyxumia was withdrawn in December 2025; the drug remains in the insulin combination Soliqua. Source for Lixisenatide
GLP-1 RALoxenatide PEG-loxenatide; PEX168Jiangsu HansohApprovedInjection, weeklyApproved in China for type 2 diabetes in May 2019; it is not approved for weight management. Source for Loxenatide
GLP-1 RAMET-224o PF-08656796PfizerDiscontinuedOralPfizer removed this oral peptide from its pipeline in August 2026 while it was in Phase 1. Source for MET-224o
GLP-1 RANoiiglutide SHR20004Jiangsu HengruiPhase 2InjectionAn obesity Phase 2 trial began in March 2021 with no registry update since 2022; a diabetes Phase 3 trial is complete. Source for Noiiglutide
GLP-1 RASemaglutide Ozempic; WegovyNovo NordiskApprovedInjection, weeklyApproved by the FDA for weight management as Wegovy in June 2021, after a 2017 diabetes approval as Ozempic. Source for Semaglutide
GLP-1 RASemaglutide oral Rybelsus; Wegovy tabletsNovo NordiskApprovedOral, dailyThe FDA approved Wegovy tablets for weight management in December 2025; the diabetes tablet dates from 2019. Source for Semaglutide oral
GLP-1 RATaspoglutideRocheDiscontinuedInjection, weeklyRoche stopped development and returned the drug to Ipsen in February 2011 after tolerability problems in Phase 3. Source for Taspoglutide
GLP-1 RATG103 efmedaglutide alfaCSPC PharmaceuticalInjection, weeklyChina's NMPA accepted a marketing application for long-term weight management in October 2025. Source for TG103
GLP-1 RAVisepegenatide PB-119PegBioApprovedInjectionChina's NMPA approved it for type 2 diabetes in November 2025; its obesity program is at Phase 1b/2a. Source for Visepegenatide
GLP-1 RAVRB-101 oral ecnoglutideVerdiva BioPhase 2Oral, weeklyOne Phase 2 trial of weekly oral ecnoglutide is complete; a second was ended in October 2026 for business reasons. Source for VRB-101
GLP-1/GIP 11 drugs
GLP-1/GIPBGM0504BrightGeneInjection, weeklyChina's NMPA accepted a marketing application for long-term weight management in June 2026. Source for BGM0504
GLP-1/GIPBrenipatide LY3537031Eli LillyPhase 1InjectionObesity work is at Phase 1; Lilly's Phase 3 trials, begun in October 2025, are in alcohol use disorder and depression. Source for Brenipatide
GLP-1/GIPEnicepatide CT-388; RO7795068RochePhase 3InjectionRoche's Phase 3 obesity trials began in March 2026. Source for Enicepatide
GLP-1/GIPHDM1005 poterepatideHuadong MedicinePhase 3Injection, weeklyA Phase 3 obesity trial in China began in October 2025; enrollment was complete by Huadong's September 2026 report. Source for HDM1005
GLP-1/GIPNNC0519-0130Novo NordiskPhase 2Injection, weeklyIts obesity Phase 2 trial ended its main phase in April 2025; Novo's Q3 2026 pipeline overview does not show it. Source for NNC0519-0130
GLP-1/GIPOlatorepatide HS-20094Hansoh Pharma; RegeneronInjection, weeklyChina's NMPA accepted a weight-management application in June 2026; Regeneron holds rights outside Greater China. Source for Olatorepatide
GLP-1/GIPRAY1225 bilpatideGuangdong Zhongsheng PharmaceuticalPhase 3Injection, every two weeksA Phase 3 obesity trial in China met its main goal in October 2026; no marketing application had been announced. Source for RAY1225
GLP-1/GIPRibupatide HRS9531; KAI-9531Jiangsu Hengrui; KaileraInjection, weeklyChina's NMPA accepted a weight-management application in September 2025; Kailera runs global Phase 3 trials. Source for Ribupatide
GLP-1/GIPTirzepatide Mounjaro; ZepboundEli LillyApprovedInjection, weeklyApproved by the FDA for weight management as Zepbound in November 2023, after a 2022 diabetes approval as Mounjaro. Source for Tirzepatide
GLP-1/GIPVK2735Viking TherapeuticsPhase 3InjectionPhase 3 trials of the injection (VANQUISH) began in June 2025 and were still running in November 2026. Source for VK2735
GLP-1/GIPVK2735 oralViking TherapeuticsPhase 3OralTwo Phase 3 trials of the tablet (SUNRISE) were listed as recruiting in November 2026. Source for VK2735 oral
GLP-1/glucagon 6 drugs
GLP-1/glucagonCotadutide MEDI0382AstraZenecaDiscontinuedInjection, dailyAstraZeneca dropped the daily injection in April 2023 to focus on a once-weekly successor. Source for Cotadutide
GLP-1/glucagonDA-1726MetaVia; Dong-A STPhase 1Injection, weeklyMetaVia's November 2026 update keeps it in Phase 1, with a Phase 2 liver-disease study planned for late 2027. Source for DA-1726
GLP-1/glucagonEfinopegdutide MK-6024Merck & Co.Phase 2Injection, weeklyMerck's November 2026 pipeline lists it in Phase 2 for the liver disease MASH; it has no active obesity trial. Source for Efinopegdutide
GLP-1/glucagonMazdutide IBI362Innovent BiologicsApprovedInjection, weeklyChina's NMPA approved it for chronic weight management in June 2025. Source for Mazdutide
GLP-1/glucagonPemvidutide ALT-801AltimmunePhase 2Injection, weeklyIts obesity Phase 2 trial ended in 2023; a Phase 3 trial in the liver disease MASH began in July 2026. Source for Pemvidutide
GLP-1/glucagonSurvodutide BI 456906Boehringer IngelheimPhase 3Injection, weeklyPhase 3 heart-safety results were reported in November 2026; Boehringer Ingelheim plans regulatory filings in 2027. Source for Survodutide
GIP/GLP-1/glucagon 4 drugs
GIP/GLP-1/glucagonEfocipegtrutide HM15211Hanmi PharmaceuticalPhase 2Injection, weeklyA Phase 2 trial in the liver disease MASH finished in July 2026; it has no obesity trial beyond Phase 1. Source for Efocipegtrutide
GIP/GLP-1/glucagonMWN101Shanghai Minwei BiotechnologyPhase 2InjectionIts obesity Phase 2 trial in China ended in November 2024; a sister compound, MWN109, entered Phase 3 in 2026. Source for MWN101
GIP/GLP-1/glucagonRetatrutide LY3437943Eli LillyPhase 3Injection, weeklyLilly reported further Phase 3 results in October 2026 and plans to file with the FDA in the first quarter of 2027. Source for Retatrutide
GIP/GLP-1/glucagonUBT251United Laboratories; Novo NordiskPhase 3InjectionA Phase 3 obesity trial in China began in September 2026; Novo Nordisk expects global Phase 1/2 results in 2027. Source for UBT251
Amylin & combos 10 drugs
Amylin & combosACCG-2671Structure TherapeuticsPhase 1OralThe multiple-dose part of a Phase 1/2a trial was under way in November 2026, with results due in early 2027. Source for ACCG-2671
Amylin & combosCagrilintideNovo NordiskPhase 3Injection, weeklyPhase 3 trials of cagrilintide on its own (RENEW) began in November 2025, with results expected in mid-2027. Source for Cagrilintide
Amylin & combosCagriSema cagrilintide + semaglutideNovo NordiskInjection, weeklyNovo Nordisk filed with the FDA in December 2025; no decision had been announced by mid-November 2026. Source for CagriSema
Amylin & combosEloralintide LY3841136Eli LillyPhase 3InjectionPhase 3 trials began in December 2025; Lilly's October 2026 pipeline lists it in Phase 3 for obesity. Source for Eloralintide
Amylin & combosEloraTZP LY900043; eloralintide + tirzepatideEli LillyPhase 3InjectionA Phase 3 trial of eloralintide combined with tirzepatide began in October 2026. Source for EloraTZP
Amylin & combosMET-233i PF-08653945PfizerPhase 2Injection, weekly or monthlyPfizer began a Phase 2b trial (SOLIS-1), alone and with berobenatide, in May 2026; results are expected in 2027. Source for MET-233i
Amylin & combosPetrelintide ZP8396; RO7895515Zealand Pharma; RochePhase 3Injection, weeklyRoche and Zealand Pharma began Phase 3 obesity trials in September 2026. Source for Petrelintide
Amylin & combosPramlintide SymlinAstraZenecaDiscontinuedInjection, at mealtimesThe FDA listed Symlin, a 2005 diabetes drug, as being discontinued by AstraZeneca in October 2025. Source for Pramlintide
Amylin & combosVRB-103Verdiva BioPhase 1OralA Phase 1 trial, alone and with oral ecnoglutide, began in July 2026. Source for VRB-103
Amylin & combosZenagamtide amycretin; NNC0487-0111Novo NordiskPhase 3InjectionPhase 3 obesity trials (AMAZE) began in February 2026; a Phase 3 trial of the oral form began in September 2026. Source for Zenagamtide
Oral small molecule 17 drugs
Oral small moleculeAleniglipron GSBR-1290Structure TherapeuticsPhase 3OralTwo Phase 3 trials (ACCOMPLISH) started in summer 2026 (company: August), with results expected in late 2028. Source for Aleniglipron
Oral small moleculeASC30 oralAscletisPhase 3Oral, dailyTwo Phase 3 trials of the once-daily tablet (AURORA) began in August 2026. Source for ASC30 oral
Oral small moleculeDanuglipron PF-06882961PfizerDiscontinuedOralPfizer ended development in April 2025 after a possible drug-related liver injury in one trial participant. Source for Danuglipron
Oral small moleculeElecoglipron AZD5004; ECC5004AstraZenecaPhase 3OralAstraZeneca's Phase 3 weight-management trials began in June 2026. Source for Elecoglipron
Oral small moleculeHDM1002 conveglipronHuadong MedicineOral, dailyChina's NMPA accepted a marketing application for long-term weight control in November 2026. Source for HDM1002
Oral small moleculeLotiglipron PF-07081532PfizerDiscontinuedOralPfizer ended development in June 2023 after raised liver enzymes were seen in trials. Source for Lotiglipron
Oral small moleculeLY4086940Eli LillyPhase 1OralPhase 1 is complete; a Phase 2 obesity trial was registered but had not begun recruiting as of November 2026. Source for LY4086940
Oral small moleculeMDR-001MindRankPhase 3OralThe first participant in a Phase 3 obesity trial in China was dosed in February 2026. Source for MDR-001
Oral small moleculeNaperiglipron LY3549492Eli LillyPhase 2OralLilly's October 2026 pipeline lists it in Phase 2; its main obesity trial finished in May 2026. Source for Naperiglipron
Oral small moleculeOrforglipron Foundayo; LY3502970Eli LillyApprovedOral, dailyThe FDA approved it for weight management as Foundayo in April 2026. Source for Orforglipron
Oral small moleculeRGT-075 RGT001-075Regor PharmaceuticalsPhase 2Oral, dailyIts most recent Phase 2 obesity trial is complete; the registry record was last updated in May 2026. Source for RGT-075
Oral small moleculeSafiglipron HRS-7535; KAI-7535Jiangsu Hengrui; KaileraOral, dailyChina's NMPA accepted a weight-management application in September 2026; Kailera runs a global Phase 2 trial. Source for Safiglipron
Oral small moleculeSAL0150Shenzhen SalubrisPhase 1Oral, weeklyA first-in-human study that includes people with obesity was registered in March 2026. Source for SAL0150
Oral small moleculeTERN-601Terns Pharmaceuticals (Merck)DiscontinuedOral, dailyTerns ended development in October 2025 after Phase 2 results; Merck acquired Terns in May 2026. Source for TERN-601
Oral small moleculeTifeglipron CT-996; RO7795081RochePhase 2Oral, dailyA Phase 2 obesity trial finished its main phase in April 2026; no Phase 3 trial is registered. Source for Tifeglipron
Oral small moleculeTQF3250Sino Biopharm (Chia Tai Tianqing)Phase 1OralA Phase 1 trial in people with overweight or obesity began in September 2026. Source for TQF3250
Oral small moleculeVCT220 CX11Vincentage Pharma; CorxelOral, dailyA marketing application in China was reported as accepted in July 2026 after a positive Phase 3 obesity trial. Source for VCT220
Other 10 drugs
OtherABBV-295 GUB014295AbbViePhase 2InjectionAbbVie began a Phase 2 trial in adults with obesity or overweight in August 2026. Source for ABBV-295
OtherAcmopatide CT-868; RO7795074RochePhase 2InjectionA Phase 2 trial in adults with type 1 diabetes and overweight or obesity is complete; record updated October 2026. Source for Acmopatide
OtherApitegromabScholar RockPhase 2InjectionA Phase 2 trial in adults with overweight or obesity is complete; the registry record was updated in January 2026. Source for Apitegromab
OtherBimagrumab LY3985863Eli LillyPhase 2InjectionLilly's October 2026 pipeline lists it in Phase 2 for obesity. Source for Bimagrumab
OtherDapiglutide ZP7570Zealand PharmaDiscontinuedInjection, weeklyZealand Pharma paused this GLP-1/GLP-2 drug after Phase 1b in November 2025 and still lists it as paused. Source for Dapiglutide
OtherEnobosarmVeruPhase 2OralA further Phase 2 trial in people with obesity or overweight began in March 2026. Source for Enobosarm
OtherGaretosmabRegeneronPhase 2InjectionA Phase 2 trial with trevogrumab and semaglutide is complete; the registry record was updated in November 2026. Source for Garetosmab
OtherMaridebart cafraglutide MariTide; AMG 133AmgenPhase 3InjectionAmgen's Phase 3 obesity trials began in March 2025; further Phase 3 trials opened in October 2026. Source for Maridebart cafraglutide
OtherPF-07976016PfizerDiscontinuedOralPfizer ended development of this GIP receptor blocker in August 2026 after reviewing Phase 2a data. Source for PF-07976016
OtherTrevogrumabRegeneronPhase 2InjectionA Phase 2 trial with semaglutide, with or without garetosmab, is complete; record updated November 2026. Source for Trevogrumab

Submitted means a regulator is reviewing the marketing application (elsewhere called Filed). Approved means approved in at least one country, not always by the FDA. Drug names open ClinicalTrials.gov in a new tab.

How to read the GLP-1 pipeline tracker

The tracker covers 79 drugs: GLP-1 medications, drugs that pair GLP-1 with other hormone targets, and a few others in trials for weight loss. List shows each drug with its class, company, status, route and a sourced note. By stage puts the same drugs in a grid from the earliest stage to Approved, minus discontinued ones.

What Phase 1, 2, 3, Submitted and Approved mean

A status is the furthest stage a drug has reached for obesity or weight management. Phase definitions are the FDA’s.1

StatusWhat it means
Phase 120 to 100 volunteers over several months, to check safety and dosage.
Phase 2Up to several hundred people with the condition, to study efficacy and side effects. About 33% move on.
Phase 3300 to 3,000 people over 1 to 4 years, to confirm benefit and monitor adverse reactions. About 25% to 30% move on.
SubmittedA regulator has accepted the company’s marketing application and is reviewing it. Elsewhere called Filed.
ApprovedApproved in at least one country. The note says where, and for what.
DiscontinuedDevelopment stopped or paused, or the product was withdrawn.

GLP-1 drug classes in the tracker

Drugs are grouped by the receptors they target.

  • GLP-1 RA (21 drugs). Agonists of the GLP-1 receptor only, such as semaglutide (Ozempic®, Wegovy®).
  • GLP-1/GIP (11). Two receptors. Tirzepatide (Mounjaro®, Zepbound®) is approved.2
  • GLP-1/glucagon (6). Survodutide and mazdutide.
  • GIP/GLP-1/glucagon (4). Triple agonists such as retatrutide.
  • Amylin and combinations (10). Cagrilintide, alone or paired with semaglutide as CagriSema.
  • Oral small molecule (17). Non-peptide pills. Orforglipron (Foundayo®) is the only approved one.3
  • Other (10). Other targets, including the antibody bimagrumab.

Which new weight loss drugs are closest to approval?

CagriSema is closest in the United States. Novo Nordisk filed it with the FDA in December 2025, and no decision had been announced by November 18, 2026.4

Retatrutide and survodutide are in Phase 3. Eli Lilly plans to submit retatrutide to the FDA in the first quarter of 2027, and Boehringer Ingelheim plans to file survodutide in 2027.5,6

The other Submitted drugs are under review in China, most recently Huadong Medicine’s daily pill HDM1002 (accepted November 2, 2026).7

Recent changes

  • December 22, 2025: FDA approval of Wegovy tablets, a daily semaglutide pill.8
  • April 1, 2026: FDA approval of orforglipron (Foundayo), a daily pill.3
  • October 7, 2026: South Korea approved efpeglenatide for weight management.9

How the data is checked, and its limits

Every row was re-checked on November 18, 2026 against a company document, a regulator, ClinicalTrials.gov or a journal, and links to its source. For 14 of the 79 drugs, part of the entry rests on trade press or could not be confirmed.

  • Statuses are for obesity. Pemvidutide is in Phase 3 for a liver disease but Phase 2 here.
  • Approved can mean approved abroad, or for diabetes rather than weight loss. The note says which.
  • Recent decisions can be missing, especially for applications in China.

What you can get through Zealthy today

Drugs still in trials are not available from Zealthy, or from anyone else outside a clinical trial. The FDA says retatrutide and cagrilintide cannot be used in compounding.10

A licensed Zealthy provider can prescribe these when appropriate for you:

  • Wegovy and Zepbound, FDA-approved for weight management.11,12
  • Ozempic and Mounjaro, FDA-approved for type 2 diabetes. Weight loss is an off-label use.2,13
  • Compounded semaglutide and compounded tirzepatide. Compounded medications are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality.10

When your plan covers a brand-name medication, the copay can be as low as $25 a month with an active Zealthy membership. See also the supply tracker and insurance coverage checker.

Get Started

GLP-1 pipeline FAQs

When will retatrutide be approved?

No approval date has been set. Retatrutide is in Phase 3, and Eli Lilly plans to submit it to the FDA in the first quarter of 2027.5 A submission starts a review and does not guarantee approval. Until then, it is available only inside a clinical trial.

Is there a GLP-1 pill for weight loss?

Yes. Two daily pills are FDA-approved for weight management: Wegovy tablets (oral semaglutide), approved December 22, 2025, and Foundayo (orforglipron), approved April 1, 2026.3,8 The tracker lists 25 oral drugs. Most are still in trials, and 5 have been discontinued.

Does Approved in the tracker mean FDA-approved?

Not always. Approved means a regulator in at least one country has approved the drug. Of the 13 Approved drugs, 6 are FDA-approved and 7 are approved only in China or South Korea. Four are for type 2 diabetes, not weight loss.

Can Zealthy prescribe retatrutide or other drugs in clinical trials?

No. Drugs still in trials are not available from Zealthy, or from anyone else outside a clinical trial. Zealthy providers prescribe Wegovy, Zepbound, Ozempic, Mounjaro, and compounded semaglutide or tirzepatide when a licensed provider finds one appropriate. Compounded medications are not FDA-approved.

What is the difference between Phase 3 and Submitted?

Phase 3 means the drug is still being tested in large trials, usually 300 to 3,000 people over 1 to 4 years.1 Submitted means a regulator has accepted the company’s application and is reviewing it. Acceptance for review is not approval.

Important safety information

Boxed warning: semaglutide and tirzepatide cause thyroid C-cell tumors in rodents; whether they do in people is unknown. Do not use them with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).11,12

Do not use them after a serious allergic reaction to the drug. Serious risks include pancreatitis, gallbladder problems, low blood sugar, kidney injury and severe stomach problems. Common side effects are nausea, diarrhea, vomiting and constipation.11,12

Full safety information: Wegovy, Zepbound, Ozempic, Mounjaro, semaglutide, tirzepatide.

Sources

  1. FDA. Step 3: Clinical Research. https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
  2. Mounjaro prescribing information. Eli Lilly. https://pi.lilly.com/us/mounjaro-uspi.pdf
  3. FDA. FDA Approves First New Molecular Entity Under National Priority Voucher Program. April 1, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
  4. Novo Nordisk. CagriSema press release, ObesityWeek 2026. https://www.novonordisk-us.com/media/press-releases/cagrisema-redefine-9-trial-obesityweek-2026.html
  5. Eli Lilly. Retatrutide Phase 3 press release, October 28, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
  6. Boehringer Ingelheim. Survodutide press release, November 9, 2026. https://www.globenewswire.com/fr/news-release/2026/11/09/3398586/0/en/boehringer-ingelheim-s-survodutide-is-the-first-glucagon-glp-1-dual-agonist-to-demonstrate-a-favorable-cardiovascular-safety-profile-in-global-phase-iii-synchronize-cvot-trial-alon.html
  7. Huadong Medicine. HDM1002 application notice. https://en.huadongmedicine.com/companynews/414/
  8. FDA. Drugs@FDA: NDA 218316, Wegovy tablets. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316
  9. Hanmi Pharmaceutical. Efpeglenatide approval press release. https://www.hanmi.co.kr/about/news-media/press/detail-5083.hm
  10. FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  11. Wegovy prescribing information. Novo Nordisk. https://www.novo-pi.com/wegovy.pdf
  12. Zepbound prescribing information. Eli Lilly. https://pi.lilly.com/us/zepbound-uspi.pdf
  13. Ozempic prescribing information. Novo Nordisk. https://www.novo-pi.com/ozempic.pdf

Start with a GLP-1 that is available today

Answer a few health questions online. A licensed provider reviews them, and membership starts at $39 for the first month.

Get Started
A Zealthy provider shown on a phone screen
Your care team

A provider works with what is approved now

A U.S.-licensed physician or nurse practitioner reviews your health history and tells you which available medication, if any, is appropriate.

50 statesLicensed providers for members in every state
No appointment neededYour intake is reviewed online, and questions are handled by message
7 days a weekSupport Monday to Friday 9am to 6pm ET, weekends 12pm to 6pm ET

The medical information on this page is reviewed by the Zealthy care team against FDA prescribing information and published clinical trials. It is general education, not personal medical advice.

Zealthy members

What Zealthy members say

One of the things I appreciate most about semaglutide is its convenience. The once-weekly dosing schedule has made it incredibly easy to integrate into my routine. It's a relief to know that I don't have to worry about multiple daily injections or complicated medication schedules.
Michelle, 33 | Lost 48 pounds
I started semaglutide at the recommendation of my Zealthy provider and I'm so happy with that decision. I signed up for their weight loss program and they've been giving me everything I need to make better lifestyle choices to get results that last. And the program's super affordable. 10/10 I can't recommend this enough.
Michael, 37 | Lost 29 pounds
Getting support a weight loss program has always been hard for me. I had been wanting to start one with a medication component for a while and Zealthy was the first one that made it easy for me with weight loss shots sent to me. They made it SO affordable and the medical team is great.
Susanne, 60 | Lost 33 pounds
Since I started, I have already lost 35 pounds and feel so much better. My doctor also helped me get a prescription for ozempic and he is always available to answer my questions in the message portal. This made me feel a lot more comfortable and excited to lose weight.
Rachel | Zealthy Member
The weight loss program is fantastic. Everyone has been so helpful and has helped me feel much more excited about the process. I was nervous to see my weight loss treatment plan, since I have done programs in the past, but they always wanted me to make drastic changes. I mentioned all of this to my weight loss coach and she was very understanding and made a customized plan for me.
John | Zealthy Member
I've been a member for 6 months now and have received all my medication every 3 months. Everyone has been so helpful and my care team is always available to help me!
Sara | Zealthy Member

Individual results may vary. These are the experiences of Zealthy members and are not a guarantee of any outcome. Medication is prescribed only when a licensed provider finds it appropriate.

Medications

GLP-1 medications Zealthy providers can prescribe

Brand-name or compounded, a licensed provider decides what fits your health history. Our insurance team handles the prior authorization paperwork for brand-name medication.

Compounded medications are prepared by a partner pharmacy for an individual prescription. They are not FDA-approved, which means the FDA has not reviewed them for safety, effectiveness or quality. Zealthy membership ($39 for the first month, then $135 a month) is billed separately from medication. A prescription is written only if a licensed provider finds it appropriate.